Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.
The assay is based on Ariel's Smart-MD bioinformatics platform, which combines patient symptoms and history with next-generation sequencing data.
The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.
Skyline will use Helomics' D-Chip bioinformatics repository of more than 149,000 tumors to develop cancer diagnostics.
The companies have partnered to jointly offer products and services for cancer specimen research and clinical data analysis.
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.
DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.
As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.
In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.